[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
25-Aug-2014

[ | E-mail ] Share Share

Contact: Shane Canning
shane.canning@biomedcentral.com
44-203-192-2429
BioMed Central
www.twitter.com/biomedcentral

RNA sequence could help doctors to tailor unique prostate cancer treatment programs

Sequencing RNA, not just DNA, could help doctors predict how prostate cancer tumors will respond to treatment, according to research published in the open access journal Genome Biology. Because a tumor's RNA shows the real time changes a treatment is causing, the authors think this could be a useful tool to aid diagnosis and predict which treatment will most benefit individual cancer patients.

Colin Collins and Alexander Wyatt, and other researchers from the Vancouver Prostate Centre at the Vancouver Coastal Health Research Institute, matched 25 patients' treatment outcomes with the RNA sequence of their prostate cancer tumors. They suggest that similarities between the RNA of some of the patients' tumors could open up new avenues of treatment.

Prostate cancer is the fourth most common cancer worldwide, but can be effectively managed. Doctors normally recommend a combination of therapies, because patients' reaction to treatment varies considerably. The side-effects of these treatments can be significant, so current research is focused around precision medicine classifying patients on their tumor's molecular changes, and only giving them the treatments that are expected to be most effective.

To investigate variations between the highest risk cases of prostate cancer, researchers conducted a range of genomic analyses, including sequencing the RNA in 25 patients' prostate tumors. The RNA molecules direct which proteins the cell produces, so the RNA sequences show how tumor cells behave differently to normal cells.

Alexander Wyatt, Vancouver Prostate Centre, says: "Most genomic sequencing studies have focused on the DNA, which gives us important information about a tumor's history. In our study we examined RNA, which tells us which genes are being used and are disrupted at the time the tumor was collected."

They then matched up this data with the detailed follow-up information that they had for each of the patients. They were then able to see what sequence disruptions were associated with a positive reaction to different therapies, and they believe this could aid personalized medicine.

Alexander Wyatt says: "We were surprised by the sheer number of genomic differences between patients. This complexity may help explain why patients respond differently to treatment, and why some tumors grow faster than others. The more we understand tumor-to-tumor variability, the closer we come to accurately tailoring a patient's management specifically for his own tumor. Overall, this is a very exciting time for cancer research, as global sequencing efforts mean we are advancing towards precision oncology."

Another potential use of this information is that in certain groups, there was a similarity in the type of genes and pathways that were disrupted in the tumors. This might indicate an underlying cancer mechanism that could be exploited to create new cancer treatments.

Alexander Wyatt says: "Despite the enormous complexity between patients at the individual gene level, when we examined the functions of affected genes, clear commonalities between groups of patients emerged. Ultimately it may be possible to exploit this convergent biology."

###

Media Contacts

Shane Canning
Media Officer
BioMed Central
T: +44 (0)20 3192 2243
E: shane.canning@biomedcentral.com

Faydra Aldridge
Director, Stakeholder Relations & Public Affairs
Vancouver Coastal Health Research Institute
T: +1 604 875 4111 x66687
E: faydra.aldridge@vch.ca

Notes to Editor

1. Research

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer Alexander W Wyatt, Fan Mo, Kendric Wang, Brian McConeghy, Sonal Brahmbhatt, Lina Jong, Devon M Mitchell, Rebecca L Johnston, Anne Haegert, Estelle Li, Janet Liew, Jake Yeung, Raunak Shrestha, Anna Lapuk, Andrew McPherson, Robert Shukin, Robert H Bell, Shawn Anderson, Jennifer Bishop, Antonio Hurtado-Coll, Hong Xiao, Arul M Chinnaiyan, Rohit Mehra, Dong Lin, Yuzhuo Wang, Ladan Fazli, Martin E Gleave, Stanislav V Volik and Colin C Collins Genome Biology 2014 15: 426

For a copy of the paper during embargo period please contact Shane Canning

After embargo, article available at journal website here: http://genomebiology.com/2014/15/8/426

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

2. Genome Biology serves the biological research community as an international forum for the dissemination, discussion and critical review of information about all areas of biology informed by genomic research. Key objectives are to provide a guide to the rapidly developing resources and technology in genomics and its impact on biological research, to publish large datasets and extensive results that are not readily accommodated in traditional journals, and to help establish new standards and nomenclature for post-genomic biology.

3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.